首页> 外文会议>Conference on single-use technologies III >EXTRACTABLES AND LEACHABLES IN CONTINUOUS PROCESSING SYSTEM
【24h】

EXTRACTABLES AND LEACHABLES IN CONTINUOUS PROCESSING SYSTEM

机译:连续处理系统中的提取物和脱色

获取原文

摘要

Single-use system and continuous processing are two significant trends in biopharmaceutical production. The two techniques are parallel and complementary to each other thus together it can provide significant improvement on drug manufacturing quality assurance as well as efficiency. While single-use system had been widely implemented for decades, adoption of continuous processing in pharmaceutical production is still in its early stage. The rapid adoption of single use technologies complements the implementation of continuous bioprocess, providing facile and enclosed systems for bioprocess manufacturing. A new generation of single-use system has been developed to fit in a continuous processing platform. Since extractables and leachables remain a major concern for single-use system adoption, each individual key component of the continuous processing system was evaluated for extractables following BPOG protocol. Risk and toxicology assessment has been performed on the extractables from critical components particularly in downstream processing. Provision of comprehensive, BPOG-aligned extractables packages for each single use bioprocessing component helps frame what extrinsic compounds and degradants may potentially leach into the process flow. However, the robust nature of these studies coupled with high surface to volume ratios may exaggerate the number and level of compounds expected to leach and persist throughout the bioprocess. From a risk assessment perspective, many of these compounds may be expected to be diluted or readily cleared during typical continuous bioprocess application steps. To evaluate the capability of the downstream purification steps to remove extractables from upstream components, samples were collected after each step in continuous processing for extractables studies. This study tracks the emergence and clearance of extractables in model fluids observed at various stages throughout a typical continuous bioprocess implementation. Few extractables in model fluids from upstream components survived after downstream purification and diafiltration steps. Subsequent evaluation of extractables in drug product in continuous processing will be in future studies.
机译:一次性系统和连续处理是生物制药生产的两种重要趋势。这两种技术彼此平行并互补地,它可以提供对药物制造质量保证以及效率的显着改善。虽然单用系统已被广泛实施数十年来,但在早期药物生产中采用连续加工仍处于早期阶段。单一用途技术的快速采用补充了连续生物过程的实施,为生物过程制造提供了便利和封闭的系统。已经开发出新一代的一次性系统来适合连续处理平台。由于萃取物和浸出物仍然是一次性系统采用的主要问题,因此对BPOP协议进行了可提取的,对连续处理系统的每个密钥组件进行了评估。在临界部件的可萃取物中,特别是在下游加工方面对风险和毒理学评估进行了风险和毒理学评估。为每个使用的BPOG对准的提取物包提供全面的BPOG对齐的可帮助组分有助于框架内在化合物和降解剂可能浸入过程流程中。然而,这些研究的鲁棒性质与高表面达到体积比可以夸大预期的化合物的数量和水平,并持续到整个生物过程中。从风险评估的角度来看,在典型的连续生物过程施加步骤期间,许多这些化合物可能会被稀释或容易地清除。为了评价下游纯化步骤的能力,以从上游组分中除去可提取物,在连续加工后收集样品以进行提取物研究。本研究追踪在整个典型的连续生物过程中在各个阶段观察到的模型流体中提取物的出现和清除。在下游净化和渗滤步骤后,来自上游组分的模型流体中的少量提取物。随后在连续处理中的药品中提取物的后续评估将在未来的研究中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号